Skip to main content

Zumenon Side Effects

Generic name: estradiol

Medically reviewed by Drugs.com. Last updated on Jan 3, 2024.

Note: This document provides detailed information about Zumenon Side Effects associated with estradiol. Some dosage forms listed on this page may not apply specifically to the brand name Zumenon.

Applies to estradiol: transdermal gel/jelly, transdermal patch extended release, transdermal spray.

Other dosage forms:

Important warnings This medicine can cause some serious health issues

Transdermal route (gel/jelly)

Endometrial Cancer, Cardiovascular Disorders, Probable Dementia, and Breast Cancer. Estrogen-Alone Therapy. Endometrial Cancer - There is an increased risk of cancer in a woman with a uterus who uses unopposed estrogens.

Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.Cardiovascular Disorders and Probable Dementia - The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo.Cardiovascular Disorders and Probable Dementia - Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia.Cardiovascular Disorders and Probable Dementia - Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI.

Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known.

Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products.

Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.Cardiovascular Disorders and Probable Dementia - Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.Estrogen Plus Progestin Therapy. Cardiovascular Disorders and Probable Dementia - The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with combined medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.Cardiovascular Disorders and Probable Dementia - The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo.

It is unknown whether this finding applies to younger postmenopausal women.Cardiovascular Disorders and Probable Dementia - Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia.Breast Cancer - The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer.Breast Cancer - Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI.

Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia, and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known.

Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products.

Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile.Breast Cancer - Prescribe estrogens with or without progestogen at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Transdermal route (patch, extended release; gel/jelly)

Estrogen Alone Therapy. Endometrial Cancer - There is an increased risk of cancer in a woman with a uterus who uses unopposed estrogens.

Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding Cardiovascular Disorders and Probable Dementia - Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia.Cardiovascular Disorders and Probable Dementia - The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo.Cardiovascular Disorders and Probable Dementia - The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo.

It is unknown whether this finding applies to younger postmenopausal women.Cardiovascular Disorders and Probable Dementia - In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.Cardiovascular Disorders and Probable Dementia - Only daily oral 0.625 mg CE was studied in the estrogen -alone substudy of the WHI.

Therefore, thee relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known.

Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products.

Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.Cardiovascular Disorders and Probable Dementia - Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.Estrogen Plus Progestin Therapy. Cardiovascular Disorders and Probable Dementia - Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia.Cardiovascular Disorders and Probable Dementia - The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with combined medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.Cardiovascular Disorders and Probable Dementia - The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo.

It is unknown whether this finding applies to younger postmenopausal women.Breast Cancer - The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer.Breast Cancer - In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.Breast Cancer - Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI.

Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia, and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known.

Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products.

Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile.Breast Cancer - Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Transdermal route (spray)

Estrogen Alone Therapy. Endometrial Cancer - There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.

Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

Perform adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal genital bleeding.Cardiovascular Disorders and Probable Dementia - The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] alone, relative to placebo.Cardiovascular Disorders and Probable Dementia - The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo.

It is unknown whether this finding applies to younger postmenopausal women.Cardiovascular Disorders and Probable Dementia - Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia.Cardiovascular Disorders and Probable Dementia - Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI.

Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known.

Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products.

Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.Cardiovascular Disorders and Probable Dementia - Prescribe estrogens with or without progestogen should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.Estrogen Plus Progestin Therapy. Cardiovascular Disorders and Probable Dementia - The WHI estrogen plus progestin substudy reported increased risks of pulmonary embolism (PE), DVT, stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.Cardiovascular Disorders and Probable Dementia - The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo.

It is unknown whether this finding applies to younger postmenopausal women.Cardiovascular Disorders and Probable Dementia - Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia.Breast Cancer - The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer.Breast Cancer - Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestogen substudy of the WHI.

Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known.

Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products.

Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile.Breast Cancer - Prescribe estrogens with or without progestogen should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.Unintentional Secondary Exposure. Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional secondary exposure to estradiol transdermal spray by women using this product.

In most cases, the condition resolved with the removal of the estradiol transdermal spray exposure.

Women should ensure that children should not come in contact with the site(s) where estradiol transdermal spray is applied.

Healthcare providers should advise patients to strictly adhere to recommended instructions for use.

Common side effects of Zumenon

Some side effects of estradiol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common side effects

  • back pain
  • difficulty with moving
  • muscle aches, pain, or stiffness
  • stuffy or runny nose

Incidence not known

  • decreased interest in sexual intercourse
  • heavy bleeding
  • increased hair growth, especially on the face
  • increased in sexual ability, desire, drive, or performance
  • increased interest in sexual intercourse
  • irritability
  • leg cramps
  • loss in sexual ability, desire, drive, or performance
  • loss of scalp hair
  • mental depression
  • mood disturbances
  • patchy brown or dark brown discoloration of the skin
  • redness of the skin
  • twitching, uncontrolled movements of the tongue, lips, face, arms, or legs
  • weight changes

Serious side effects of Zumenon

Along with its needed effects, estradiol (the active ingredient contained in Zumenon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking estradiol:

Incidence not known

  • acid or sour stomach
  • anxiety
  • backache
  • belching
  • blistering, peeling, or loosening of the skin
  • bloating
  • blurred vision
  • breast tenderness, enlargement, pain, or discharge
  • change in vaginal discharge
  • changes in skin color
  • changes in vision
  • chest pain, discomfort, or tightness
  • chills
  • clay-colored stools
  • clear or bloody discharge from the nipple
  • confusion
  • constipation
  • cough
  • darkening of the urine
  • diarrhea
  • difficulty with swallowing
  • dimpling of the breast skin
  • dizziness or lightheadedness
  • double vision
  • fainting
  • fast heartbeat
  • fever
  • fluid-filled skin blisters
  • full or bloated feeling or pressure in the stomach
  • headache
  • headache, severe and throbbing
  • heartburn
  • hives, itching, skin rash
  • indigestion
  • inverted nipple
  • irregular heartbeat
  • itching of the vagina or genital area
  • joint or muscle pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • light-colored stools
  • loss of appetite
  • loss of bladder control
  • lump in the breast or under the arm
  • migraine headache
  • mood or mental changes
  • muscle cramps in the hands, arms, feet, legs, or face
  • muscle spasm or jerking of all extremities
  • nausea
  • noisy breathing
  • numbness and tingling around the mouth, fingertips, or feet
  • pain during sexual intercourse
  • pain in the ankles or knees
  • pain or discomfort in the arms, jaw, back, or neck
  • pain or feeling of pressure in the pelvis
  • pain, redness, or swelling in the arm, foot, or leg
  • painful, red lumps under the skin, mostly on the legs
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • persistent crusting or scaling of the nipple
  • poor insight and judgment
  • problems with memory or speech
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red, irritated eyes
  • redness or swelling of the breast
  • seizures
  • sensitivity to the sun
  • skin thinness
  • sore on the skin of the breast that does not heal
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • stomach cramps, discomfort, upset, pain, or swelling
  • sudden loss of consciousness
  • sudden trouble breathing
  • sweating
  • thick, white vaginal discharge with no odor or with a mild odor
  • tremor
  • trouble recognizing objects
  • trouble thinking and planning
  • trouble walking
  • unexpected or excess milk flow from the breasts
  • unpleasant breath odor
  • unusual tiredness or weakness
  • unusually heavy or unexpected menstrual bleeding
  • vaginal bleeding or spotting
  • vomiting
  • vomiting of blood
  • yellow eyes or skin
Managing side effects (general information)

For healthcare professionals

Applies to estradiol: compounding powder, intramuscular solution, oral tablet, transdermal emulsion, transdermal film extended release, transdermal gel, transdermal spray, vaginal ring.

Genitourinary adverse events

Gastrointestinal

Musculoskeletal

Cardiovascular

Nervous system

Oncologic

Other

Psychiatric

Dermatologic

Ocular

Hepatic

Metabolic

Hypersensitivity

Immunologic

Local

References

1. Auerbach R, Mittal K, Schwartz PE (1988) "Estrogen and progestin receptors in an ovarian ependymoma." Obstet Gynecol, 71, p. 1043-5

2. Julian TM (1987) "Pseudoincontinence secondary to unopposed estrogen replacement in the surgically castrate premenopausal female." Obstet Gynecol, 70, p. 382-3

3. (2001) "Product Information. Climara (estradiol)." Berlex Laboratories

4. (2001) "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories

5. Nash HA, AlvarezSanchez F, Mishell DR, Fraser IS, Maruo T, Harmon TM (1999) "Estradiol-delivering vaginal rings for hormone replacement therapy." Am J Obstet Gynecol, 181, p. 1400-6

6. Cerner Multum, Inc. "Australian Product Information."

7. (2017) "Product Information. Yuvafem (estradiol topical)." AvKare Inc

8. (2017) "Product Information. Estradiol Vaginal Insert (estradiol topical)." Teva Pharmaceuticals USA

9. Boston Collaborative Drug Surveilance Program (1974) "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med, 290, p. 15-9

10. Crane MG, Harris JJ (1978) "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci, 276, p. 33-55

11. Crane MG, Harris JJ, Winsor W 3d (1971) "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med, 74, p. 13-21

12. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS (1980) "Noncontraceptive estrogens and myocardial infarction in young women." JAMA, 244, p. 339-42

13. Jick H, Dinan B, Rothman KJ (1978) "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA, 239, p. 1407-8

14. Wren BG, Routledge DA (1981) "Blood pressure changes: oestrogens in climacteric women." Med J Aust, 2, p. 528-31

15. Belchetz PE (1994) "Hormonal treatment of postmenopausal women." N Engl J Med, 330, p. 1062-71

16. Stampfer MJ, Colditz GA, Willett WC, et al. (1991) "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med, 325, p. 756-62

17. Barrett-Connor E, Bush TL (1991) "Estrogen and coronary heart disease in women." JAMA, 265, p. 1861-7

18. Grady D, Rubin SM, Petiti DB, et al. (1992) "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med, 117, p. 1016-36

19. Barrett-Connor E, Wingard DL, Criqui MH (1989) "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA, 261, p. 1095-2100

20. Schwartz J, Freeman R, Frishman W (1995) "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol, 35, p. 1-16

21. The Writing Group for the PEPI Trial (1995) "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA, 273, p. 199-208

22. Collins P, Beale CM, Rosano GMC (1996) "Oestrogen as a calcium channel blocker." Eur Heart J, 17 ( Suppl, p. 27-31

23. Bui MN, Arai AE, Hathaway L, Waclawiw MA, Csako G, Cannon RO 3rd (2002) "Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women." Am J Cardiol, 90, p. 82-5

24. Steiger MJ, Quinn NP (1991) "Hormone replacement therapy induced chorea." BMJ, 302, p. 762

25. Cohen L, Coxwell WL, Melchione T, Koltun W, Gibson E, Gupta N, Roberts M (1999) "Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausal women." Curr Ther Res Clin Exp, 60, p. 534-47

26. Obrink A, Bunne G, Collen J, Tjernberg B (1979) "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand, 58, p. 123

27. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S (1991) "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol, 134, p. 1386-95

28. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S (1991) "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol, 134, p. 1375-85

29. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW (1981) "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol, 114, p. 497-506

30. Thomas DB, Persing JP, Hutchinson WB (1982) "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst, 69, p. 1017-25

31. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R (1979) "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med, 300, p. 9-13

32. Gordon J, Reagan JW, Finkle WD, Ziel HK (1977) "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med, 297, p. 570-1

33. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C (1989) "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med, 321, p. 293-7

34. Gray LA Sr, Christopherson WM, Hoover RN (1977) "Estrogens and endometrial carcinoma." Obstet Gynecol, 49, p. 385-9

35. Colditz GA, Hankinson SE, Hunter DJ, et al. (1995) "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med, 332, p. 1589-93

36. The Writing Group for the PEPI Trial (1996) "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA, 275, p. 370-5

37. Gapstur SM, Morrow M, Sellers TA (1999) "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women's health study." JAMA, 281, p. 2091-7

38. Oppenheim G (1984) "A case of rapid mood cycling with estrogen: implications for therapy." J Clin Psychiatry, 45, p. 34-5

39. Conter RL, Longmire WP Jr (1988) "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg, 207, p. 115-9

40. Aldinger K, Ben-Menachem Y, Whalen G (1977) "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med, 137, p. 357-9

41. Molitch ME, Oill P, Odell WD (1974) "Massive hyperlipemia during estrogen therapy." JAMA, 227, p. 522-5

Further information

Zumenon side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer